Aimed 온라인 바카라 사이트: “IPO is just the beginning…Advancing through ADC technology transfers and human data acquisition”

[by Yu, Suin] "I believe that a public listing is not an endpoint but the beginning. Through global technology transfers and the accumulation of human clinical data, we will continue to grow into a patient-centered company, in line with our founding vision."

Her Nam-gu, CEO of Aimed 온라인 바카라 사이트, spoke with <THE 온라인 바카라 사이트 on October 8 during ‘온라인 바카라 사이트Japan 2025’ in Yokohama, Japan. Despite the Thanksgiving holiday (Chuseok), Her traveled to Japan at the invitation of the Korea Drug Development Fund (KDDF). He is scheduled to participate as the sole Korean 온라인 바카라 사이트technology company panelist at the KDDF-sponsored session on October 9, which will address the theme ‘Global Expansion Strategies for Global, Japanese, and Korean Companies."

"This year has been exceptionally busy, with IPO preparations and numerous global partnering meetings taking up most of my time. However, the Chuseok holiday was the only brief window in my schedule, so I decided to use that opportunity to attend 온라인 바카라 사이트Japan. This marks my first participation in the event," he explained.

Regarding his participation as a session panelist, he remarked, "The topic itself was highly engaging, and as the sole representative of Korean 온라인 바카라 사이트technology, I felt it was meaningful to share insights from the perspective of Korea’s 온라인 바카라 사이트tech industry." He added, "I intend to discuss the importance of global collaboration, the practical processes involved in partnerships and out-licensing, the key factors for successful international cooperation, and my views on the future trajectory of the Korean 온라인 바카라 사이트pharmaceutical ecosystem."

Aimed 온라인 바카라 사이트 plans to pursue numerous partnership opportunities during 온라인 바카라 사이트Japan 2025, aiming to expand its global network and explore new pipeline collaborations to drive post-IPO growth. "I had so many meetings that it was challenging to manage them all on my own. I reviewed the progress of our existing collaborations with companies specializing in antibody-drug conjugates (ADCs), artificial intelligence (AI), and antibody technologies, while also meeting a wide range of potential partners to explore new opportunities for technology transfer and co-development," Her stated.

“We have a diverse series of meetings scheduled with both global and Japanese companies, and notably, the proportion of Japanese pharmaceutical firms has increased compared to previous years,” he further commented. “By using the Japanese market as a strategic springboard, we aim to broaden our partnerships not only across Asia but also into the global arena.”

Aimed 온라인 바카라 사이트, a 온라인 바카라 사이트pharmaceutical company specializing in the development of ADCs, was established in 2018 as a spinoff from Samsung Medical Center. Since its founding, the company has demonstrated strong technological capabilities, notably by licensing out ‘AMB302’ (development code) to 온라인 바카라 사이트haven in the United States in 2024 and by signing a co-development and licensing agreement for ‘AMB303’ with SK Plasma in June of this year.

Aimed 온라인 바카라 사이트 is also preparing for an initial public offering (IPO) as part of its strategy to strengthen its position in the global ADC market. The move is intended to secure the necessary capital to support the company’s participation in the industry's shift toward next-generation platforms, including bispecific antibody ADCs. The company has already raised KRW 51.1 billion (approximately USD 35.9 million) through pre-IPO equity financing, bringing its total cumulative investment since its founding to KRW 113.5 billion.

According to a recent securities report, Aimed 온라인 바카라 사이트 plans to raise approximately KRW 58 billion through its upcoming KOSDAQ listing, with the majority of the funds allocated to research and development (R&D) and platform development. "Although we are nearing our IPO, this marks only the beginning. We intend to remain focused on our original goal: achieving a higher level of innovation and growth," Her remarked.

"To achieve this goal, we must secure stronger global partners and pursue additional technology transfer opportunities. At present, one of our follow-on ADC pipeline candidates appears to hold the greatest potential, and although it is difficult to predict a specific timeline, we remain optimistic about the results," he further added. "Up to now, our focus has been primarily on technology transfer, but moving forward, we plan to enhance our human data capabilities, as these will play a critical role in driving the company's future growth."